KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Gross Margin (2018 - 2025)

Historic Gross Margin for Ionis Pharmaceuticals (IONS) over the last 8 years, with Q3 2025 value amounting to 98.51%.

  • Ionis Pharmaceuticals' Gross Margin fell 6900.0% to 98.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 98.51%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 98.41% for FY2024, which is 4300.0% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Gross Margin of 98.51% as of Q3 2025, which was down 6900.0% from 98.51% recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Gross Margin ranged from a high of 99.49% in Q4 2021 and a low of 96.45% during Q2 2022
  • Moreover, its 5-year median value for Gross Margin was 98.48% (2023), whereas its average is 98.29%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 208200bps in 2021, then tumbled by -19200bps in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' Gross Margin (Quarter) stood at 99.49% in 2021, then dropped by -2bps to 97.57% in 2022, then rose by 2bps to 99.06% in 2023, then dropped by -1bps to 98.31% in 2024, then rose by 0bps to 98.51% in 2025.
  • Its Gross Margin was 98.51% in Q3 2025, compared to 98.51% in Q2 2025 and 98.89% in Q1 2025.